Key result
Perioperative acadesine did not reduce the composite of mortality, stroke, or severe LV dysfunction compared to placebo in patients undergoing CABG surgery (5.1% vs 5.0%; OR 1.01; 95% CI 0.73-1.41).
Why the study?
Does perioperative acadesine reduce the composite of all-cause mortality, nonfatal stroke, or severe left ventricular dysfunction in intermediate- to high-risk patients undergoing nonemergency, on-pump CABG surgery?
RCT (n=3,080)
Double-blind
1:1
Yes
Does perioperative acadesine reduce the composite of all-cause mortality, nonfatal stroke, or severe left ventricular dysfunction in intermediate- to high-risk patients undergoing nonemergency, on-pump CABG surgery?
Odds Ratio: 1.01 (95% CI 0.73–1.41)
Absolute Event Rate: 5.1% vs 5%
Perioperative administration of the adenosine-regulating agent acadesine does not reduce the risk of mortality, stroke, or severe left ventricular dysfunction in patients undergoing on-pump CABG surgery.
No takes yet. Share an insight, caveat, or question.
Clinicians should avoid perioperative acadesine in CABG; confirms lack of efficacy in a definitive multicenter RCT.
Newman et al. (2012) conducted an RCT in Coronary artery bypass graft (CABG) surgery (n=3,080). Acadesine vs. Placebo was evaluated on Composite of all-cause mortality, nonfatal stroke, or need for mechanical support for SLVD during and following CABG surgery through postoperative day 28 (OR 1.01, 95% CI 0.73-1.41). Perioperative acadesine did not reduce the composite of mortality, stroke, or severe LV dysfunction compared to placebo in patients undergoing CABG surgery (5.1% vs 5.0%; OR 1.01; 95% CI 0.73-1.41).
Synapse has enriched 4 closely related papers on similar clinical questions. Consider them for comparative context: